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     To my family 
  
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Dagens samhälle är till stor del beroende av kemiska ämnen. De finns i låga halter i 
praktiskt taget allting som används i det vardagliga livet; till exempel i mat, vatten, 
hygienprodukter, kläder och leksaker. Många exponeras också för höga halter av 
kemikalier i sin arbetsmiljö. Vissa av kemikalierna kan vara skadliga för hälsan. Hur 
skadliga de är beror bland annat på ämnets inneboende egenskaper och hur hög 
exponeringen är, samt hur ofta och länge som man exponeras (dosen). Hur mycket av 
ämnet som tas upp av kroppen och som når det organ där det utövar sin effekt 
(måldosen) styr också hur skadligt ämnet är. Individuella skillnader i till exempel ålder, 
kön, arvsanlag och hur fysiskt aktiv man är påverkar måldosens storlek och därmed 
också hur allvarliga hälsoeffekterna blir.  
 
För att skydda människor från hälsoproblem som orsakas av kemiska ämnen sätter 
myndigheter gränsvärden som reglerar hur hög exponeringen får vara, till exempel i 
arbetslivet. Kunskapen om hur och vid vilken exponeringsnivå människor påverkas av 
olika kemiska ämnen är emellertid begränsad. Gränsvärden tas därför oftast fram 
genom att dela den högsta dos som inte har någon effekt i försöksdjur med ett antal s.k. 
bedömningsfaktorer. I de flesta fall används schablonvärden för att ta hänsyn till 
skillnader mellan djur och människor och skillnader mellan individer. Sedan dessa togs 
fram på 1950-talet har mängden information om kemiska ämnen, deras påverkan på 
hälsan och skillnader i känslighet mellan människor ökat markant.  
 
Syftet med de studier som ingår i avhandlingen var att utveckla en metod för att ta fram 
vetenskapligt baserade bedömningsfaktorer som beskriver skillnader i måldosen mellan 
människor. Metoden tillämpades sedan på fyra vanliga organiska lösningsmedel; 
aceton, toluen, styren och metylklorid.   
 
I Studie I utvecklades en matematisk modell som räknar ut måldosen efter exponering 
för aceton. Modellen baserades på kunskap om människans anatomi, om olika 
biologiska och kemiska processer samt på acetons specifika egenskaper. För att kunna 
använda matematiska modeller i arbetet med att sätta gränsvärden är det viktigt att först 
verifiera dem med hjälp av experimentella observationer. I Studie II användes därför ett 
statistiskt ramverk för att jämföra och uppdatera de för aceton beräknade måldoserna 
med mätdata från friska frivilliga försökspersoner som exponerats för aceton. Den 
uppdaterade modellen användes därefter, tillsammans med andra, redan utvecklade 
modeller för toluen, styren och metylklorid, för att simulera måldosen hos olika 
befolkningsgrupper (Studie III och IV). Vi undersökte bland annat vilken effekt ålder 
och kön hade i den allmänna befolkningen och vilken effekt kön, variationer i 
exponeringsnivå och i fysisk arbetsbelastning över tid hade på måldosen hos 
yrkesexponerade.  
 
Resultaten tyder på att schablonvärdena är tillräckliga eller något höga för 
allmänbefolkningen, även då man tar hänsyn till skillnader i ålder och kön. För 
  
yrkesmässigt exponerade kan de däremot vara otillräckliga då exponeringsnivån 
varierar över tid, speciellt om den fysiska arbetsbelastningen också varierar.  
 
Studierna som ingår i den här avhandlingen kan bidra till att öka tillförlitligheten hos de 
gränsvärden som reglerar exponering för kemiska ämnen. Genom att ersätta 
schablonvärdena med vetenskapligt baserade bedömningsfaktorer kan för höga 
gränsvärden, med försämrad hälsa hos befolkningen och stora kostnader för samhället, 
förhindras. Onödigt låga gränsvärden, med långtgående ekonomiska konsekvenser för 
både näringsliv och samhälle, kan också undvikas. 
  
ABSTRACT 
Exposure limits or guidelines are derived to protect humans from adverse effects 
caused by exposure to chemical substances in the environment or at the workplace. The 
internal dose of a chemical is determined by toxicokinetic (TK) processes such as 
uptake, distribution and elimination, and is closely related to the risk of adversity. The 
internal dose varies among individuals due to differences in age, genetics, physical 
activity, health status and life-style. Thus, it is important to address population 
variability for the exposure limits to be protective. TK variability is typically accounted 
for by the use of a default assessment factor of 3.16. However, the scientific basis of the 
exposure limits may be improved by replacing the default value with a chemical 
specific adjustment factor (CSAFHK), derived from experimental data. By doing so, 
more appropriate exposure limits are achieved, and large costs for society associated 
with both too high and too low exposure limits may be avoided.  
 
Substitution of the default value is often obstructed by the lack of suitable experimental 
data. In this thesis, this limitation was addressed by the development of a probabilistic 
framework using physiologically based pharmacokinetic (PBPK) modeling. It was used 
to derive CSAFHK for four commonly used organic solvents; acetone, toluene, styrene 
and methyl chloride. 
 
PBPK models based on information on anatomical, physiological and biochemical 
parameters were used to calculate the internal doses following inhalation exposure to 
the four chemicals. A description of washin-washout in the respiratory tract was 
evolved for polar solvents such as acetone. Additional information on the model 
parameters contained in human experimental toxicokinetic data was taken advantage of 
by Bayesian analysis. Meanwhile, the methodology was explored with respect to prior 
assumptions. CSAFHK were derived from population distributions of internal dose 
obtained by Monte Carlo (MC) simulation from distributions of the model parameters. 
The influence of age and gender on the internal dose was slight. Thus, the factors 
obtained for all substances were below 2.5. However, the effects of fluctuations in 
exposure level and workload increased the CSAFHK up to 6.1, indicating that workplace 
exposure may need specific attention. Given the diverse properties of acetone, toluene, 
styrene and methyl chloride, the results can probably be generalized to most organic 
solvents and similar chemicals.  
 
The CSAFHK presented in this thesis are derived from extensive information on 
intraspecies toxicokinetic differences and cover the effects of common toxicokinetic 
modifiers. Thus, they are well suited to replace the default value. The population 
framework may be further extended to include other chemicals, as well as additional 
experimental data on population variability when such becomes available. 
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 INTRODUCTION 1
 
Chemical substances are essential parts of human lives and abundant in our 
surroundings. Thus, humans are exposed to them on a daily basis in occupational as 
well as in residential settings. Chemicals can be harmful to human health, depending 
on their inherent properties, the exposure scenario, and on individual susceptibility 
and behavior. 
 
Health risk assessment is used to determine if a particular chemical is harmful to human 
health and, if so, under what circumstances. This information is used to derive exposure 
standards aiming at protecting most individuals in a population from the harm of 
exposure. In such efforts, information on human variability in response to chemical 
exposure is important. Human exposure standards are typically based on the highest 
dose or exposure level at which the negative health effect is not detected in animals (No 
Observed Adverse Effect Level - NOAEL). To determine an exposure level which is 
considered to be safe for humans, the NOEAL is divided by a number of assessment 
factors.  
  
A so-called default assessment factor (AF) of 10 has traditionally been used to address 
human variability. The default AF is based on limited scientific information, thus 
making its use in human health risk assessment associated with considerable 
uncertainty. In recent years, possibilities to replace the default value with more realistic, 
data-driven ones have emerged by the increase of available experimental toxicological 
data to quantify human variability, and advances in modeling and computer simulation. 
 
Improving the scientific basis for assessment factors would contribute to more reliable 
exposure standards for chemical substances. Thus, too high exposure standards 
resulting in illness in a population could be avoided. Illness is not only affecting the 
wellbeing of individuals, but also has high costs for society. Unnecessarily low 
exposure standards could also be avoided. Such standards may have far reaching 
economic consequences for industry, as well as for society.  
  
 2 
 AIM 2
 
The overall aim of this thesis was to improve the scientific basis of human health risk 
assessment factors by quantifying intraspecies (human to human) variability in the 
toxicokinetics of organic volatiles.  
 
The specific aims were to; 
 construct a physiologically based pharmacokinetic (PBPK) model for the 
inhalation of polar organic solvents, using acetone as an example (paper I) 
 
 calibrate the PBPK model for acetone to human  experimental toxicokinetic 
data using Bayesian analysis (paper II) 
 
 develop a probabilistic framework for the derivation of chemical specific 
adjustment factors for human toxicokinetic variability (CSAFHK) using acetone 
as an example (paper III) 
 
 derive CSAFHK for non-polar solvents such as toluene, styrene and methyl 
chloride by deploying existing PBPK models and the probabilistic framework 
(paper IV) 
 
 evaluate the effect of age and gender on intraspecies toxicokinetic variability 
(paper III and IV) 
 
 investigate the effect of various workplace conditions, such as ventilation rates, 
fluctuations in exposure level and workload on inter-worker toxicokinetic 
variability (paper III and IV) 
  
   3 
 BACKGROUND 3
3.1 ORGANIC SOLVENTS 
Organic solvents are liquids capable of dissolving other organic substances. Due to 
their attractive properties they are commonly used in industrial processes and in 
manufacturing of a wide range of products. They are also found in many household 
commodities. Since the use of organic solvents is so common, the exposure to humans 
is widespread.
1
 For example, it has been estimated that 10 million US workers are 
potentially exposed to organic solvents.
2
 In the United Kingdom 8 percent of the 
working population is thought to regularly handle organic solvents.
3
 Organic solvents 
can cause both acute and chronic health effects. Acute health effects typically follows 
from a single significant exposure and are often reversible. Common acute effects from 
solvent exposure are for example irritation of the eye, nose, and throat as well as 
headaches, loss of coordination and nausea.
4,5
 Conversely, chronic health effects are 
caused by prolonged or repeated exposures over many days, months or years. Thus, 
they typically do not occur immediately and are often irreversible. Chronic health 
effects from solvent exposure include among other damage to liver, kidney and central 
nervous system (CNS), and cancer.
5-9
 
  
3.2 DOSE - RESPONSE 
Exposure to organic solvents may be harmful to human health. The risk of adversity 
is determined by a number of factors, such as the inherent properties of the substance 
and the dose, i.e. the magnitude, duration and frequency of the exposure. Adversity is 
also dependent on the toxicokinetics of the substance, i.e. how much of the substance 
that enters the body and what happens to it well inside, as well as on how the 
chemical interacts with the body or its mode of action (toxicodynamics). Although 
the dose is the same, the magnitude of the response will typically vary among humans 
as a consequence of individual differences in the kinetic and/or dynamic processes. 
Variation in response may also be caused by differences in susceptibility and 
behavior.  
 
3.3 HUMAN HEALTH RISK ASSESSMENT 
Toxicological risk assessment may be performed to determine the probability of 
chemical substances to cause adverse health effects in a human population of concern. 
It involves determining the inherent potential of the chemical substance to cause harm, 
the human dose-response relationship and, the likelihood and the extent of the exposure 
in the population.
10
  
 
Dose-response assessment typically starts by identifying a critical health effect and a 
dose or exposure level at which this effect is not detected (NOAEL) or found to be 
minimal (Lowest Observed Adverse Effect Level - LOAEL).
10
 In this process, priority 
is generally given to human data. However, as such studies are rare studies of effects in 
experimental animals are in most cases used instead. 
 
 4 
To convert the NOEAL or LOAEL value into an exposure level considered to be of no 
concern for humans, adjustments may be necessary. They are typically performed for 
the use of animal data, to cater for variability between humans and for other data lacks, 
such as uncertainties relating to exposure duration or route.
11
 For this purpose, 
assessment (uncertainty, adjustment, extrapolation, safety, conversion) factors are used 
by considering the possibility that humans may be more sensitive than animals to the 
negative effects of chemical substances. Thus, to derive human exposure standards, the 
NOAEL/LOAEL is divided by the product of the assessment factors (AF); 
 
 uman e  osure standard    
  AE 
∏A 
     (1) 
 
3.3.1 Assessment factors 
Default assessment factors 
Default assessment factors are numerical values traditionally used to compensate for 
the lack of full information on the effects of chemical substances in human 
populations.
12-14
 They were first introduced in the United States in the mid-1950s by 
Lehman and Fitzhugh.
15
 The suggested 100-fold factor was derived based on a 
comparison of the knowledge of the toxicity of fluorine in rats and arsenic in dogs with 
the supposed toxicity in humans. Although based on a comparison between species, the 
factor was also considered to compensate for variability within a population.
11,14,15
 
Since then, the default factor of 100 has been slightly modified to separately account 
for interspecies (animal to human) and intraspecies (human to human) variability. 
Values of 10 were suggested for both adjustments.
16,17
 The factors are commonly 
assumed to be independent and are hence multiplied.  
 
Chemical specific adjustment factors (CSAF) 
Default AFs are deployed to compensate for lack of knowledge. Thus, when relevant 
information is available it should be used instead.
18
 To enable data describing 
differences from toxicokinetic or toxicodynamic effects to be incorporated separately, 
the default uncertainty factors of 10 were further sub-divided.
19-21
 For intraspecies 
variability, factors of 3.16 (10
0.5
) were derived for toxicokinetic and toxicodynamic 
effects, respectively.
10,21,22
 The subdivision of the 100 fold factor is depicted in Figure 
1. 
 
 
 
   5 
 
 
Figure 1. Division of the 100-fold factor according to WHO/IPCS.
21
 This thesis focuses on the 
highlighted part. 
 
 
General population and workers 
Health risk assessments typically aim at the general or the occupationally exposed 
populations. The two populations differ in a number of ways, the most important being 
the exposure scenario and the potential susceptibility of the individuals.  
 
Exposure to the general population is often continuous and life-long to low levels of 
chemicals whereas in an occupational setting the exposure is shorter termed and 
repeated (generally 8 hours a day, 5 days a week). Workers are typically exposed to 
higher levels than the general population and the exposure is more often carried out 
during strenuous physical activity. The general population is more heterogeneous than 
the occupationally exposed population as it includes individuals who might be 
especially sensitive to the exposure of chemical substances, such as children, the 
elderly and individuals with pre-existing medical conditions. Workers are typically 
healthy adults.  
 
These differences are sometimes reflected in the size of the default value applied by 
different exposure standard setting organizations. Thus, the guidance document of the 
European REACH regulation proposes default AFs of 5 and 10,
23
 the Dutch TNO 
(Netherlands organization for Applied Scientific Research) has proposed AFs of 3 and 
10, and the European Centre for Ecotoxicology and Toxicology of Chemicals 
(ECETOC) has suggested AFs of 3 and 5, for the working and general population, 
respectively.  An additional AF has sometimes also been applied to protect children and 
infants as they may be especially susceptible to the harm of chemical substances during 
development.
24,25
 
 
Following the same principle as for the subdivision of the default assessment factor of 
10 (section 3.3.1), the toxicokinetic moiety for inter-worker variability would be 
between 1.7 and 2.2 (3
0.5
 and 5
0.5
). 
 6 
3.4 TOXICOKINETICS OF ORGANIC SOLVENTS 
Exposure standards or guidelines have traditionally been based on measures of 
external dose, for example the administered dose or the concentration of a chemical 
substance in ambient air. However, adversity is often more closely related to the 
amount of the chemical substance that reaches the tissue or the organ where it exerts 
its effect (internal dose). The internal dose is determined by biological and 
physiological processes which govern the uptake, distribution and elimination of the 
chemical.  
 
3.4.1 Uptake 
This thesis focuses on uptake via inhalation, the most common route of exposure to 
organic solvents.
26
 However, they are also taken up via the skin.
27
 Organic solvents are 
typically adsorbed by passive diffusion along their concentration gradient. The amount 
which is taken up by the body depends on the characteristics of the solvent and the 
barriers it has to cross to enter.
28
 During inhalation, air, together with any volatile it 
contains, travels via the nose and mouth to the trachea and further into the bronchi 
(Figure 2). The bronchi branches dichotomously in the lungs and become increasingly 
smaller in diameter until they end in small air sacs, called alveoli. The walls of the 
alveoli are very thin and richly supplied with capillaries. They cover up to 90 percent of 
the alveolar surface and receive the entire cardiac output.
29,30
 Thus, chemical vapors 
can easily travel through the walls of the alveoli to enter the systemic circulation.  
 
The respiratory airways are lined with a thin layer of epithelial tissue which secretes 
mucus. The function of the mucosa is to condition the inhaled air with moisture and to 
trap pathogens, dirt, and particles.
31
 Polar (hydrophilic) solvents may be absorbed by 
the mucosa during inhalation, and subsequently be released during exhalation (washin-
washout effect). Hence, a fraction of the inhaled solvent vapor will not participate in 
the gas-exchange in the alveoli.
32,33
 However, it may still reach the systemic circulation 
via exchange trough the bronchial walls.
34-37
  
 
3.4.2 Distribution 
Once the solvent has reached the systemic blood flow it is carried throughout the body 
and into organs and tissues. The extent of the distribution is determined by the solvent’s 
properties and the characteristics of the tissue membranes.
28
 Distribution of organic 
solvents typically occurs by passive diffusion. 
 
   7 
  
 
Figure 2. The respiratory airways. Image from Wikimedia.
38
 
 
 
3.4.3 Elimination 
Elimination of chemical substances occurs via metabolism and excretion. During 
metabolism, solvents are transformed into more hydrophilic compounds. Such 
compounds are generally less toxic and easier for the body to dispose of. However, 
some chemicals undergo metabolic activation. In such cases the metabolite is more 
toxic than the parent compound and thus responsible for the toxic effect. There are 
typically two phases in the biotransformation process. The function of phase I reactions 
is to add or expose functional groups to which hydrophilic molecules can be bound by 
phase II reactions.
28
 The phase I, cytochrome P450 (CYP450) reactions are thought to 
be the most important in the metabolism of organic solvents.
39
 The biotransformation 
enzymes are mainly present in liver, but large amounts also exists in lung, kidney and 
in the skin. Small amounts can be found in almost any tissue in the human body.
26
 
Organic solvents are excreted as such, or as a metabolite after biotransformation. 
Excretion occurs into urine via the kidneys or into feces via the biliary route. 
Unchanged solvent may also be exhaled. 
 
3.4.4 Intraspecies variability 
The extent of the uptake, distribution and elimination of chemical substances varies 
between individuals. As a consequence, the magnitude of the internal dose and hence 
the risk of adversity will vary within a human population. Factors that have been shown 
 8 
to modify the kinetics of inhaled organic solvents in humans include among others; age, 
gender, physical exercise, and metabolism.
26,40-43
 Variability may also be due to lack of 
knowledge, i.e. uncertainty.
44,45
  
 
Age 
Substantial differences in the toxicokinetics of solvents may occur as a consequence of 
age.
43
 Due to their rapid development, children are also more variable within a defined 
age group than adults.
46
 Children may have a larger pulmonary uptake than adults as 
they breathe more relative to their body size.
47
 Children also tend to be more physically 
active than adults.
48
 During physical activity, lung ventilation increases. This may 
increase the uptake of inhaled volatiles in children as compared to adults. Children also 
have different proportions of fat, muscle and water as compared to adults. The body 
water content in children is higher, and it also varies greatly with age.
49,50
 Fat content 
also varies during development.
50
 Such differences may affect the distribution of 
organic solvents. In general, children metabolize more relative to their body size. The 
increased metabolism has been argued to compensate for any increased exposure.
51
 
However, in cases where the metabolite is responsible for the toxic effect, the increased 
metabolic capacity may put children at larger risk of adverse health effects. Moreover, 
metabolism and excretion in very young children may be immature.
52-54
 For example, 
the levels of the CYP450 enzymes reach adult levels first at the age of 2-6 months.
52
 
The activity of other important biotransformation enzymes may also be decreased in 
young children.
43
  
 
Gender 
Most of the observed gender differences of the toxicokinetics of organic solvents may 
be explained by differences in body size, however not all of them. In general, females 
have a higher percentage of body fat than men. As a consequence, they may receive 
higher internal doses of lipophilic solvents. Moreover, females may have a prolonged 
internal exposure to lipophilic substances after the end of the ambient exposure due to 
the increased storage opportunity.
26
  
 
Physical activity  
Exposure to organic solvents typically occurs during the performance of various 
tasks. These tasks may require various levels of physical activity. Physical activity 
has been shown to alter the toxicokinetics of a large number of volatiles.
26,37,40,55
 An 
increase in workload increases pulmonary ventilation and cardiac output.
37
 The 
cardiac output is also redistributed, with active muscles, fat and skin receiving 
relatively larger portions of the blood flow whereas the blood flow to liver, gastro-
intestinal tract and kidneys decreases.
37,40
 The metabolism can thus be affected 
indirectly by the decrease in blood flow to liver. Elimination of solvents by 
exhalation may be increased by an increase in ventilation.
26
 The influence of physical 
activity on the toxicokinetics is chemical dependent, however in general, exposure 
during physical exercise results in an increase of the internal dose and higher risk of 
adverse effects compared to exposure at rest.
26,40
  
 
   9 
Metabolic capacity 
Different members of the cytochrome P450 enzyme family (CYP) are primarily 
responsible for the biotransformation of organic solvents in humans. In addition, 
several other enzymes are involved. Thus, intraspecies differences in the toxicokinetics 
of organic solvents may partly be explained by differences in metabolic activity. For 
example, up to 10-fold differences in CYP activity has been seen in humans.
56,57
 
Genetic polymorphisms have been detected for several enzymes involved in the 
biotransformation of organic solvents, such as CYP1A1 and GSTT1.
58
 Individuals can 
either be poor, fast or non-metabolizers dependent on the number of copies of the 
functional gene. More than a tenfold variation in metabolic capacity due to genetic 
polymorphism in biotransformation enzymes has been reported.
59
 At low exposure 
levels, a linear relationship between the exposure level and internal dose can be 
expected. However, at higher exposure levels metabolism can become saturated. 
Saturation results in a disproportional change of the internal doses metrics and may 
contribute to a higher intraspecies variability in toxicokinetics of organic solvents.
26
   
 
Measurement uncertainty  
The experimentally determined concentrations of a chemical substance in a biomarker 
(blood, breath or urine) vary between individuals at the same exposure scenario. 
Likewise, the measurements of physiological parameters, such as ventilation rates or 
body weight vary among humans. Such differences may be due to biological 
variability, but could also be a consequence of erroneous or imprecise measurements, 
or most likely, the combination of both.
60
 Thus, observed intraspecies differences can 
be attributed both to biological variability and uncertainty. Uncertainty can be 
distinguished from biological variability as it can be reduced by performing new 
experiments or by gathering more information. Biological variability on the other hand 
is an intrinsic property of living systems which size cannot be affected or altered by an 
increase in knowledge.  
 
3.5 PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS 
Physiologically based pharmacokinetic (PBPK) models attempt to describe the 
processes of uptake, distribution and elimination of a substance in mathematical 
terms, based on knowledge on human anatomy and physiological mechanisms. Thus, 
they can be used to calculate the internal dose of a chemical substance based on the 
external exposure. In the scientific literature, the term physiologically based 
toxicokinetic (PBTK) model is also used. 
 
A typical PBPK model for inhalation exposure to non-polar solvent vapors is shown in 
Figure 3. It contains special compartments for exchange of solvent between inhaled air 
and systemic blood, and for the storage of solvent in fat. The metabolism of the solvent 
is assumed to occur in liver by a single pathway. 
 
A PBPK model arranges the organs or tissues in compartments and links them with 
perfusing blood. The structure of the model is partly determined by its intended use, 
and partly by the knowledge of the kinetics of the substance of interest. Thus, the 
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model typically includes separate compartments for target tissues, tissues responsible 
for biotransformation, storage tissues and tissues for which experimental data is 
available. The model also includes the exposure route(s). Remaining tissues can be 
lumped in joint compartments based on similarities in blood flow rates and tissue; 
blood partition coefficients. Common practice is to minimize the complexity of the 
model to reduce data needs and computational time. The compartments are typically 
assumed to be well-stirred and perfusion rate limited. A mass-balance differential 
equation is used to describe the movement of the substance in each compartment. The 
set of differential equations are solved by numerical integration to predict the amount of 
chemical substance in the tissue(s) of interest over time. 
 
Measurements of the physiological, physiochemical and biochemical parameters 
included in the PBPK model equations may be derived from the scientific literature, 
vital statistics, or other sources and incorporated in the model. These are for example 
the ventilation rate, organ volumes, perfusion rates, and the partition coefficients and 
metabolic parameters of the chemical substance. 
 
 
 
 
Figure 3. The structure of a typical PBPK model for an inhaled non-polar solvent. 
 
 
To evaluate the performance of the PBPK model, it is often validated against 
experimental toxicokinetic data. In most cases it is necessary to refine the model due to 
disagreement between the model predictions and observations. Refinement can be 
achieved by changes in the model structure, and/or by calibration. During calibration, 
values or distributions of the model parameters that yield the best agreement between 
the model predictions and experimental observations are derived.  
 
PBPK models are attractive tools in toxicological risk assessment.
61-64
 Apart from being 
able to calculate the internal dose after a chemical exposure they are also applicable in 
many of the extrapolations performed in order to estimate human health risks from 
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experimental data. Since PBPK models are anatomically based and therefore the same 
for all mammals, they can be used to extrapolate between different species, age groups, 
gender and conditions by only changing the values of the model parameters.  
 
3.6 MODELING OF TOXICOKINETIC VARIABILITY  
Population variability of the internal dose can be estimated by Monte Carlo (MC) 
simulation from distributions of the PBPK model parameters.
60
 The distributions 
describe the variability of the parameters in the human population. During MC 
sampling random values are iteratively drawn from the distributions and used as inputs 
to the PBPK model. Thus, the result obtained from such a simulation is a population 
distribution of internal dose.  
 
To make accurate predictions of population dose metrics for regulatory use, it is 
essential to first calibrate the PBPK model to experimental toxicokinetic data.
65
 
Calibration of PBPK models is not an easy task. PBPK models often involve non-linear 
biological processes, co-varying model parameters, and different levels of biological 
variability in both model parameter distributions and experimental data. In addition, 
uncertainty due to lack of knowledge may be important. Calibration of PBPK models is 
therefore conveniently performed in a Bayesian hierarchical framework.
66
 
 
Hierarchical (population) models 
Hierarchical models describe the variability within a large population based on 
observations from few individuals.
67
 The main idea is that a common model describes 
all individuals, but that the model parameters may differ between them. Some of the 
parameters are measured in the experimental studies and are considered known. By 
letting remaining, unknown, parameters belong to a statistical distribution, they can be 
estimated from the experimental data for the individual as well as for the population.
68
 
Meanwhile, different sources of variability, such as biological variability and 
uncertainty, can be separated.
44,69-71
  
 
Bayesian inference  
In a Bayesian analysis, the calibration of the hierarchical PBPK model to 
experimental toxicokinetic data is facilitated by the use of previous knowledge. 
Knowledge on the model parameters can be derived from the scientific literature. The 
previous knowledge is expressed by its probability and hence summarized as 
distributions. These prior parameter distributions are then updated with information in 
experimental toxicokinetic data to yield posterior distributions which are in 
agreement with both previous knowledge and the observations. The updating of the 
prior distributions is performed according to strict rules, given the likelihood of a 
given set of parameters to yield the observed experimental data. 
 
Markov chain Monte Carlo simulation 
Posterior distributions can be generated using numerical methods such as Markov 
chain Monte Carlo simulation (MCMC). In a first step, random parameter values are 
sampled from the prior distributions using Monte Carlo simulation to initiate one or 
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several Markov chains. The PBPK model makes a prediction of the time course of the 
chemical in blood based on the given parameter set. MCMC is an iterative process, 
thus for each iteration, new parameter sets are generated and new predictions are 
made. Based on how well the predictions and experimental observations agree, the 
new parameter set will be kept or rejected. Following a large number of iterations, the 
prior distributions will converge to create stationary distributions, called posterior 
distributions.
72,73
 Convergence is assessed by one or several formal criteria.
74
  
 
Following convergence, the chains can be run further to obtain population 
distributions of the model parameters. From these, population distributions of internal 
dose can be simulated by using the PBPK model and simple forward Monte Carlo 
sampling. 
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4.1 MODELING SUBSTANCES 
Acetone, toluene, styrene and methyl chloride are organic solvents commonly used in 
industry. Except for methyl chloride, they are also common in many household 
commodities. They are all high volume chemicals, with production exceeding 450 tons 
per year.
75
 Besides having many similar properties, acetone, toluene, styrene and 
methyl chloride are also quite diverse. Thus, they allow for range of properties which 
may affect the toxicokinetics of organic solvents to be explored. The admissible 
exposure levels of the four chemicals vary between standard setting organizations and 
countries. In this thesis, the Reference Concentrations (RfC) for continuous exposure 
during a lifetime set by the United States Environmental Protection Agency (US EPA) 
were used to simulate exposure to the general population, whereas the threshold limit 
values (TLV) recommended by the American Conference of Governmental Industrial 
Hygienists (ACGIH) for average concentrations in air on the basis of a 8 h a day and 40 
h per week work schedule were used for occupational exposure.  
 
4.1.1 Acetone 
Acetone is produced naturally by many plants and mammals, including humans, as a 
result of the breakdown and utilization of stored fats and lipids as a source of 
energy.
76
 However, industrial processes contribute more acetone to the environment 
than natural processes. Acetone is used to produce for example plastics, fibers, drugs, 
and other chemicals. The toxicity of acetone is mediated by the parent compound and 
exposure to moderate-to-high amounts may cause effects on the CNS, and irritation of 
the respiratory tract and eyes.
77
 Acetone is a polar solvent. Thus, it has high solubility 
in blood (blood; air partition coefficient PBA of about 220) and poor solubility in fat 
(fat; blood partition coefficient, PFatB of 0.23) (Paper II, Table 3). Acetone is 
metabolized by CYP2E1. Due to the lack of data, an RfC has not yet been established 
by the US EPA. Thus, in this thesis the suggested RfC of 29 ppm was used.
78
 ACGIH 
recommends a TLV of 500 ppm for occupational exposure.
79
 The National Institute of 
Occupational Safety and Health Administration (NIOSH) estimates that 1.74 million 
people, of which 31 percent are females, are occupationally exposed to acetone in the 
US.
2
  
 
4.1.2 Toluene 
Workers are mainly exposed to toluene is in the production of gasoline, but toluene is 
also frequently used to produce paints and lacquers.
80
 Exposure to the general 
population is generally through the use of household products containing toluene, but 
cigarette smoke is also an important source. Both chronic and acute effects from 
toluene exposure are thought to be derived from the direct action of the parent 
compound on receptors in the brain.
81-83
 Toluene is a non-polar solvent with low blood 
solubility, and high affinity for fat (PBA of 16 and PFatB of 54, Paper IV Table 4). 
Toluene is primarily metabolized by different members of the CYP family.
84
 The RfC 
set by the US EPA is 1.3 ppm.
85
 About 2 million US workers are estimated to be 
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exposed to toluene at their workplace.
2
 19 percent of these are females. The TLV 
recommended by ACGIH is 20 ppm.
79
 
 
4.1.3 Styrene 
Occupational exposure to styrene occurs through manufacturing and processing of 
polystyrene plastics and resins. The general population is exposed to styrene from 
anthropogenic origin and by cigarette smoke. The CNS depressant effect of acute 
exposures to styrene levels is probably due to direct effect of the unchanged styrene 
on nerve cell membranes. The chronic toxicity is however thought to be mediated 
through one or several metabolites.
86,87
 Metabolism of styrene occurs mainly by 
members of the CYP family to styrene-oxide. The exact mechanism for the chronic 
effects of styrene exposure is not known, however binding of styrene-oxide to various 
components of the nerve tissue has been proposed as a probable mechanism.
88,89
 
Styrene is a non-polar solvent. It is moderately soluble in blood and has high fat 
solubility (PBA of 64 and PFatB of 49, Paper IV Table 4). The RfC is 0.24 ppm.
90
 About 
330 000 US workers are supposed to be exposed to styrene vapor at their work place. 
26 percent of them are estimated to be female.
2
 The TLV recommended for styrene is 
20 ppm.
79
 
 
4.1.4 Methyl chloride 
The general population is primarily exposed to methyl chloride produced naturally by 
algae, kelp and fungi. However for smokers, cigarettes are probably the most important 
source. Occupational exposure to methyl chloride occurs mainly in the production of 
silicones.
91
 Acute exposure to methyl chloride has caused severe neurological effects in 
humans. Methyl chloride is also known to cause effects on the heart rate, blood 
pressure, liver, and kidneys in humans. The toxic entity of methyl chloride is 
presumably a metabolite, however the mechanism of action is unknown.
92 Mehyl 
chloride is a non-polar solvent. It has low blood- and moderate fat solubility (PBA of 1.7 
and PFatB of 6, Paper IV Table 4). Most of the inhaled methyl chloride is metabolized 
by GSTT1.
93
 GSTT1 is polymorphic and have a tri-modal distribution reflecting fast, 
slow and non-conjugators.
94,95
 The RfC is 0.04 ppm.
96
 10 000 workers in the US are 
potentially exposed to methyl chloride, of which 6 percent are female.
2
 The 
recommended TLV is 50 ppm.
79 
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4.2 HUMAN EXPERIMENTAL DATA (PAPERS I AND II) 
The human toxicokinetic data for acetone came from a total of 18 male 
volunteers.
97,98
 The volunteers were exposed while performing physical exercise on a 
bicycle ergometer. Extensive sampling of blood and breath was performed during and 
after the end of the exposure. The collection of exhaled air from a volunteer is 
depicted in Figure 4. 
 
 
 
 
Figure 4. Sampling of exhaled breath through a mouthpiece. 
 
 
In 1981, 8 male volunteers were exposed to acetone vapor at two separate 
occasions.
98
 The first time all 8 volunteers were exposed at rest to approximately 550 
ppm of acetone vapor (series I). On the second occasion, the exposure level was 
approximately 290 ppm during 2 hours. 4 of the volunteers were exposed at rest for 
30 minutes followed by 50W workload for 90 minutes, and the remaining 4 
volunteers were exposed while performing a stepwise increase in workload from rest 
to 50, 100 and 150 W. Each workload scenario lasted 30 min. In 1999, 10 male 
volunteers were exposed to approximately 250 ppm acetone for 2 hours during light 
physical exercise (50 W).
97
  
 
4.3 PBPK MODELS 
4.3.1 Acetone (Papers I, II and III) 
The acetone PBPK model is based on a typical model for inhalation with compartments 
for lungs, richly perfused tissues, fat, liver, and muscles and skin (Figure 5). It accounts 
for the effect of washin-washout in the respiratory airways, physical exercise and 
endogenous acetone production. Washin-washout of solvent vapor in the lung is 
described by modeling the lung by using four separate compartments; bronchioles, 
mucosa, alveolae and arterial blood. Solvent vapor is allowed to be exchanged with the 
systemic blood in the bronchioles via the mucosa, as well as in the alveolar region. 
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Figure 5. The acetone PBPK model structure. The washin-washout effect of solvent vapor in 
the upper respiratory tract is described by using four separate compartments for the lung.  
 
 
The change in the concentration of acetone in the respiratory tract over time (dC/dt) is 
described by the following four differential equations: 
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where Q and P signifies flows and partition coefficients respectively. C and V denotes 
concentrations and volumes. Subscripts connotes; alv: alveolar, c: cardiac, inh: 
inhaled, bro: bronchioles, muc: mucosa, art: arterial, b:a: blood:air, w:a: water:air, t: 
tissue. 
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The increased blood flow to leg muscle during bicycle exercise is reflected by 
modeling resting muscle and skin, and working muscle separately.
99
 Production of 
endogenous acetone, as well as acetone metabolism is included in the liver. 
 
4.3.2 Toluene (Paper IV) 
The toluene PBPK model include compartments for lungs and arterial blood, well 
perfused tissues, fat, muscles, and liver (Figure 6a).
95
 The fat compartment is split in 
subcutaneous and perirenal fat, and resting and working muscles are modeled 
separately.
99
 Metabolism occurs in both liver and lungs (i.e. the lung and arterial blood 
compartment).
100
 The model is calibrated in a statistical framework using experimental 
data from 6 subjects exposed to 80 ppm of toluene for four consecutive 30-min periods 
during rest and exercise at increasing workloads of 50, 100 and 150 W.
101,102
 The 
experimental data include frequently recorded levels of toluene in arterial blood, end-
exhaled air and subcutaneous fat tissue.  
 
 
 
 
Figure 6. PBPK model structures for a) toluene, b) styrene and c) methyl chloride. 
 
 
4.3.3 Styrene (Paper IV) 
The styrene PBPK model include compartments for lungs and arterial blood, well 
perfused tissues, subcutaneous fat, perirenal fat, working muscles, resting muscles, and 
liver (Figure 6b).
103
 Saturable metabolism is described in the liver. The styrene PBPK 
model is calibrated to experimental data in a hierarchical Bayesian framework. It was 
fitted to measured levels of styrene in arterial and venous blood, subcutaneous fat and 
end-exhaled air recorded from 24 individuals from three different exposure studies. The 
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volunteers were exposed during 120 minutes at styrene levels of between 50 and 350 
ppm at rest or while performing physical activity at workloads of up to 150 W.
104-106
 
 
4.3.4 Methyl chloride (Paper IV) 
The methyl chloride population PBPK model include six compartments; lungs and 
arterial blood, well perfused tissues, working muscle, resting muscle, fat and liver 
(Figure 6c).
107
 The model was developed for non-conjugators and hence elimination 
was originally only by exhalation. The model is calibrated to observed levels of methyl 
chloride in arterialized capillary blood and exhaled air from 8 individuals exposed to 10 
ppm of methyl chloride vapor during 120 minutes while performing light physical 
exercise (50 W).
108
 In this thesis, a clearance term was added to the PBPK model to 
account for metabolism of conjugators (Paper IV).
58,93-95,109
 The experimentally 
estimated clearance exceeds liver blood flow for both fast and slow conjugators.
58
 
Thus, metabolism was for simplicity assumed to occur in blood (i.e. the lung and 
arterial blood compartment). 
 
4.4 PBPK MODEL PARAMETERIZATION 
4.4.1 Experimentally measured parameters (Papers I and II) 
Some of the model parameters were measured in the experimental studies of exposure 
to acetone and were hence adopted in the PBPK model for acetone.
97,98
 In both 
studies, body weight (BW), body height (BH), pulmonary ventilation rates and 
endogenous acetone levels (unpublished data) were measure. In addition, the 
individual exposure levels were measured throughout the exposure (unpublished 
data). Oxygen uptake and respiratory frequency were measured in one of the 
studies.
98
 The individual model parameters are given in Paper I, Table 2 and Paper II, 
Table 2.  
 
4.4.2 Scaled model parameters (Papers I, II and III) 
To account for known physiological relationships between parameters the acetone 
PBPK model parameters were as far as possible scaled to covariates. Organ volumes 
were scaled to BW and BH. The rate of exchange of acetone via the mucosa is scaled to 
alveolar ventilation rate and cardiac output. The scaling of the remaining model 
parameters differs between the three published papers on acetone and is described 
below. 
  
Paper I  
Pulmonary ventilation rates were determined by experimental data. The alveolar 
ventilation rate was calculated from the pulmonary ventilation rate by subtracting the 
product of breathing frequency and dead space. Alveolar ventilation was in turn used to 
calculate the cardiac output by using the perfusion over ventilation ratio (PVR). 
Subsequently, organ blood flows were calculated as fractions of the cardiac output 
based on values for organ blood flows reported by Åstrand.
37
 Acetone metabolism was 
scaled to BW
0.75
 and described by Michaelis-Menten kinetics (saturable metabolism). 
The scaling is described in detail in Paper I (Tables 2 and 3). 
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Papers II and III  
Blood flows were scaled to BW and BH. Cardiac output was calculated as the sum of 
the contributions from each organ, and was linked to alveolar ventilation via the PVR. 
Alveolar ventilation was in turn related to pulmonary ventilation by adding dead-space 
ventilation. The physiological changes during physical activity was considered 
proportional to the excess oxygen uptake above rest.
110
 The change of tissue perfusion 
with physical exercise was described by equations previously derived by Droz and 
coworkers
111
 and based on reference values suggested by Åstrand.
37
 The metabolism 
was scaled to BW and BH, assumed to be first order and described by intrinsic 
clearance. The scaling is described in detail in Paper II, Table 1 and Paper III, Table 2.  
 
4.4.3 Prior distributions (Paper II) 
The compartment volumes, the volume of the dead space and the perfusion over 
ventilation ratio were considered known with precision. Prior distributions were 
defined for the remaining model parameters by complying with the philosophy of 
information gathering in Bayesian statistics, thus incorporating new information based 
on current knowledge. Thus, the prior distributions used as starting points for 
calibration of the acetone PBPK model were mainly derived from posteriors from the 
previously calibrated PBPK model for styrene.
103
 Distribution of the parameters 
governing the washin-washout effect and the acetone chemical-specific model 
parameters were defined based on the summary of available evidence in the literature. 
Details on the derivation of prior distribution are given in Paper II (Tables 3 and 4 and 
the Appendix). 
 
4.5 HIERARCHICAL MODEL (PAPER II) 
The statistical model used in the calibration of the acetone PBPK model had two 
levels; one representing the volunteers participating in the experimental studies and 
one representing the population. It is schematically represented in Figure 7. At the 
individual level, each volunteer is represented by the measured parameters ( ) (e.g. 
exposure level, BW, BH oxygen uptake and lung ventilation rates) and the observed 
concentrations of acetone blood and breath over time. The remaining, unknown 
individual parameters (θ) are considered samples from a population distribution and 
were defined by prior distributions. The PBPK model can predict the time-
concentration profile for an individual given   and θ. The prediction is then 
compared with the observations. They will differ due to errors in experimental 
measurements, and in model- or parameter specification. Thus, errors were defined 
for each experimental biomarker (arterial- and venous blood and mixed- and end-
exhaled air) while assuming that the errors were independent, identical in the two 
experimental studies and log-normally distributed with mean 0 and variance σ2. As µ 
and , as well as σ2 are not known with precision they were considered associated 
with uncertainty and hence expressed by probability distributions. Lognormal 
distributions were chosen for the population means (µ) while inverse gamma 
distributions were used for the population variability (),112 and error σ2.113,114 
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4.6 MARKOV CHAIN MONTE CARLO SIMULATION (PAPER II) 
The calibration of the acetone PBPK model to the human experimental toxicokinetic 
data was performed via MCMC simulation using Metropolis-Hastings sampling.
74
 
The simulations were performed in the McSim software.
115
 Convergence was 
assessed in the Bayesian Output Analysis Program (BOA),
116
 using the criterion of 
Gelman and Rubin,
73
 and by visual inspection of the chains. 
 
 
 
 
Figure 7. The hierarchical model used in the calibration of the PBPK model for acetone. 
The PBPK model can predict the concentrations of acetone for each individual (i) from the 
experimentally measured parameters ( ) and unknown parameters ( ). The unknown 
parameters are defined at the population level by their mean ( ) and variability ( ). The 
deviation between
 
the model predictions and the data is represented by σ2.  
 
 
4.7 MONTE CARLO SIMULATIONS (PAPERS III AND IV) 
4.7.1 Dose metrics 
The amount of parent compound or metabolite in blood (or other biomarkers), i.e. the 
surrogate dose, is generally thought to be a good indication of the internal dose. The 
choice of surrogate doses for acetone, toluene, styrene and methyl chloride was based 
on information about the toxic entity of each solvent (section 4.1).  
 
Markers for chronic effects 
The surrogate doses for chronic effects from exposure to acetone and toluene were 
the 24 hour integrated concentration (AUC24h) of parent compound in blood. For 
styrene and methyl chloride the metabolized amount during 24 hours, normalized to 
BW
0.75
 (Met24h) was chosen. 
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Markers for acute effects 
Acute effects for all four chemical substances were represented by the maximal 
concentration of parent compound in blood (CMax). 
 
4.7.2 Exposure scenarios 
General population 
Monte Carlo simulations were performed in 8 different sub-populations; 3 month old 
babies, 1 year, 5 year and 10 year old children, 15 year old males and females, and 
adult males and females. The individuals were assumed to be continuously exposed to 
solvent levels air corresponding to the set or suggested RfC while performing physical 
activity according to reference values for daily time budgets, specific for each 
subpopulation.
117
  
 
The impact of endogenous acetone levels could be important during low dose 
exposures. Therefore, the simulations in the general population both included and 
excluded endogenous acetone.  
 
The outcome of 10 000 MC simulations was collected for each sub-population and 
activity level. The simulations were performed using the McSim software.
115
 
 
Workers  
The male and female workers were assumed to be exposed to the TLVs recommended 
by ACGIH, from 8 am to 12 pm, and from 1 pm to 5 pm. During lunch (12 am to 1 pm) 
and from 5 pm to 8 am the next morning the exposure was set to 0 ppm. Light physical 
exercise was assumed during the morning and afternoon shifts. During lunch, from 5 
pm to 11 pm and between 7 am and 8 am the workload was half of what was applied 
during the shifts. During night (11 pm to 7 am) the workers were resting. The influence 
of fluctuating exposure and workload, and workplace ventilation rate on the surrogate 
doses was investigated by simulating six different exposure scenarios; 
 
 Constant exposure and constant workload 
 
 Constant exposure and fluctuating workload  
 
 Fluctuating exposure with slow air exchange, and constant workload  
 
 Fluctuating exposure with rapid air exchange, and constant workload 
 
 Fluctuating exposure with slow air exchange, and fluctuating workload  
 
 Fluctuating exposure with rapid air exchange, and fluctuating workload 
 
The outcome of 10 000 MC simulations was collected for each gender and exposure 
scenario. The simulations were performed using the McSim software.
115
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4.7.3 Distributions of the model parameters 
The parameter distributions representing BW, body mass index (BMI), oxygen 
uptake and BH were derived from vital statistics or the scientific literature. 
Remaining parameters distributions were defined by the posteriors from previous 
calibrations of the acetone, toluene, styrene and methyl chloride PBPK models (used 
mainly for adult males),
97,101,105,115
 and model parameter distributions collected from 
the scientific literature (used mainly for adult females and children).  
 
4.7.4 Calculation of CSAFHK (Papers III and IV) 
The chemical specific adjustment factors for human toxicokinetic variability (CSAFHK) 
were derived based on the 90
th
, 95
th
 and the 97.5
th
 percentile of simulated surrogate 
doses in a given population.
21
 Hence, they are considered to protect 90, 95 and 97.5 
percent of the individuals in the population. CSAFHK were derived by dividing the n
th
 
(where n is 90, 95 and 97.5) percentile of surrogate doses in each sub-population, with 
the median surrogate dose in the whole population. The distribution of surrogate doses 
in whole general population was obtained by collecting surrogate doses from each sub-
population while considering its proportion of the Swedish population.
118
 The surrogate 
doses representing the whole worker population were calculated in a similar manner by 
collecting those obtained by simulating constant exposure and constant workload, while 
considering the proportion of females in industry with potential exposure to acetone 
(26% of workers), toluene (19%), styrene (26%) and methyl chloride (6%).
2
 For methyl 
chloride, the proportion of the Swedish population belonging to each GSTT1 genotype 
was also considered (11.1% null; 46.2% slow; and 42.8% fast conjugators).
119
 In the 
calculation of CSAFHK for methyl chloride, the fast and non-conjugators were 
considered the most sensitive group for chronic and acute effects, respectively.  
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 RESULTS 5
 
5.1 PBPK MODEL FOR ACETONE (PAPER I) 
A washin-washout PBPK model for acetone (described in Section 4.3.1) was developed 
in Paper I. The model predictions were compared to those obtained by using an inert 
tube PBPK model. The wasin-washout model allows pre-alveolar utake of inhaled 
acetone, whereas the the conducting airways of an inert tube model are assumed only to 
transport the solvent vapor to the alveoli, where all gas exchange occurs (an example of 
an inert tube model is depicted in Figure 3). The washin-washout model was able to 
accurately predict average acetone levels in blood and breath sampled from 16 
inhalation experiments with 8 male volunteers exposed to acetone levels ranging from 
250-550 ppm, during various levels of physical activity. In contrast, the inert tube 
model was unable to describe the experimental data, especially in exhaled air (Figure 
8). 
 
 
Figure 8. Washin-washout (solid lines) and inert-tube model (dotted lines) predictions are 
compared to experimental acetone concentrations (circles) in arterial blood and exhaled air. a) 
Exposure to 540 ppm for 120 minutes during resting conditions. b) Exposure to 290 ppm for 30 
minutes at rest followed by 90 minutes of physical exercise at 50 W workload. c) Exposure to 
290 ppm for 30 minutes at rest followed by a stepwise increase in workload (50, 100, 150 W) 
for 30 minute periods.  
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To evaluate the predictive power of the finalized acetone washin-washout PBPK model 
it was applied on a new dataset which was withheld during the model specification. The 
predictions of acetone in arterial blood and mixed exhaled air agreed well with the 
observed levels of acetone (Figure 9) 
 
 
 
 
Figure 9. Predictive power of the washin-washout PBPK model. The prediction of average 
acetone levels in blood and breath is compared to observed levels from 10 male volunteers 
exposed during 120 minutes to 250 ppm of acetone during the performance of physical exercise 
at 50W workload. 
 
 
5.2 ACETONE PBPK MODEL CALIBRATION (PAPER II) 
In Paper II, the washin-washout PBPK model for acetone was calibrated to 
experimental toxicokinetic data from 18 male volunteers exposed to 250-550 ppm of 
acetone while performing physical activity (section 4.2) in a Bayesian hierarchical 
framework using MCMC simulation. This was done to obtain improved estimates of 
population variability and uncertainty of the PBPK model parameters, especially for 
those related to the washin-washout behavior of polar volatile substances. Meanwhile, 
the sensitivity of PBPK model to the prior assumptions was investigated.  
 
5.2.1 Sensitivity analysis 
The sensitivity analysis indicated that for most physiological model parameters no new 
information on population variability could be obtained from the experimental 
toxicokinetic data. Thus, in subsequent MCMC simulations population variability was 
estimated only for clearance and the parameters governing the washin-washout of 
acetone in the airways. 
 
5.2.2 Posterior distributions 
Following the calibration of the acetone PBPK model to the experimental data, the 
precision of most of the population parameter estimates was improved. Moreover, most 
parameters were found to be uncorrelated (Paper II, Table 4). New information was 
particularly gained on the population distribution of the parameters governing the 
washin-washout effect. The population mean and variability of the model parameters 
are listed Table 1, along with the relative change of the posterior estimates compared to 
the prior distributions.  
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Table 1. Posterior distributions of the acetone PBPK model parameters summarized by the 
 o ulation mean (µ) and variability (Σ), with associated uncertainties, UC (coefficient of 
variation). The percent change from the prior distribution is also indicated. A negative sign 
implies that the precision of the posterior estimate was improved compared to the prior. 
 
 
    a
 arithmetic mean 
    b
 coefficient of variation of the mean 
 
 
5.2.3 Validation 
To validate the calibrated PBPK model, the experimentally observed acetone 
concentrations in arterial- and venous blood and end- and mixed exhaled air were 
simulated by using the PBPK model, the experimentally determined model parameters 
and subject-specific posterior estimates. In general, the predictions agreed well with the 
observed concentrations (Figure 10). However, the predictions of acetone levels in 
breath at low concentrations were not as precise as the other predictions (Figure 10 b 
and d). 
 
 
 
 
Acetone PBPK model parameter 
Posterior distribution Change from prior (%) 
µ
a
 (UCM) Σ
b
 (UCV) µ(UCM) Σ(UCV) 
Unit perfusion (l/(min · l tissue)) 
QCFat Fat 0.02 (0.11) -   0 (1) - 
QCRpt Richly perfused tissues 0.75 (0.05) - - 6 (-5) - 
QCMus Muscle and skin 0.04 (0.01) -  33 (-9) - 
QCLiv Liver 0.85 (0.08) - - 3 (-2) - 
Perfusion change with exercise (l/(min · l tissue) / (l O2/min)) 
Work
FatQC  Fat 0.01 (0.22) - 0 (-4) - 
Work
RptQC  Richly perfused tissues 0.22 (0.05) - 22 (-5) - 
Work
WmQC  Working muscle 6.91 (0.01) - -18 (-12) - 
Work
LivQC  Liver 0.14 (0.12) - 8 (-1) - 
Metabolism (l/(min∙l liver)) 
CL Clearance 0.07 (0.07) 0.37 (0.24) 0 (-2) 11(14) 
Washin-washout 
QCBroMuc 
Fractional transfer between 
bronchioles and mucosa 
0.89 (0.06) 0.30 (0.42) 11 (-4) 0 (-158) 
QCMucArt 
Fractional transfer between 
mucosa and arterial blood 
0.74 (0.10) 1.00 (0.10) -8 (0) 70 (-190) 
Partition coefficients 
PFatA Fat:air 82 (0.11) - -5 (-5) - 
PRptA Richly perfused tissues:air 208 (0.02) - 52 (-26) - 
PMusA Muscle:air 195 (0.02) - 29 (-47) - 
PLivA Liver:air 192 (0.07) - 14 (-43) - 
PBA Blood:air 221 (0.00) - -22 (-11) - 
PWA Water:air 354 (0.08) - 1 (-1) - 
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Figure 10. Predicted versus observed acetone concentrations in a) arterial blood, b) end-
exhaled air, c) venous blood, and d) mixed exhaled air. 
 
  
5.3 HUMAN TOXICOKINETIC VARIABILITY (PAPERS III AND IV) 
CSAFHK for acetone, toluene, styrene and methyl chloride were derived by Monte 
Carlo simulation, combining PBPK models for respective solvent, population 
distributions of the model parameters from previous Bayesian analyses, vital statistics 
and published distributions of physiological and anatomical parameters for adult 
females and children. The simulations covered how factors such as age and gender in 
the general population, and fluctuations in workplace air concentration and workload 
influenced the surrogate doses in adult female and male workers. For acetone, the 
influence on the surrogate doses by endogenous production was also investigated. 
Chronic effects of solvent exposure were considered important in the general 
population as well as for workers. In workers, acute effects of solvent exposure were 
also explored. CSAFHK were calculated for the 90
th
, 95
th
 and the 97.5
th
 percentiles of 
simulated surrogate doses in each population as a whole, in each sub-population and for 
each exposure scenario. The CSAFHK reported below were derived at the most 
commonly used 95
th
 percentile, thus considered to protect 95 percent of the individuals 
in the population. The factors at the other percentiles were marginally different. The 
CSAFHK for acetone are tabulated in Paper III (Tables 6, 7 and 8). The CSAFHK for 
toluene, styrene and methyl chloride are tabulated in Paper IV (Appendices A and B). 
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5.3.1 Acetone 
General population 
In the whole population, the intraspecies differences of surrogate dose were accounted 
for by a CSAFHK of 1.9 (Figure 11 and Paper III, Table 6). However, endogenous 
acetone levels had a significant influence on the predicted surrogate doses. Thus, a 
factor 2.9 was obtained when including variability from endogenous sources (Paper III, 
Table 6). Higher CSAFHK were obtained in children.  Hence, factors up to 2.4 and 5.5 
(including endogenous acetone) were derived. The CSAFHK obtained for males were 
slightly higher compared to the ones derived for females.  
 
 
 
 
Figure 11. CSAFHK for acetone, toluene, styrene and methyl chloride for chronic effects in the 
general population. The CSAFHK for acetone excludes variability from endogenous sources. 
The CSAFHK for methyl chloride represent sub-populations homozygous for GSTT1 (i.e fast 
conjugators), thus having the highest metabolism in the population. 
 
 
Workers 
During conditions of constant exposure and workload, CSAFHK of 1.5 (chronic) and 1.3 
(acute) were derived for the entire workforce (Figures 12 and 13). The influence of 
fluctuating exposure or workload on the derived CSAFHK was small. However, the 
combined effect of fluctuations in both exposure and workload increased the CSAFHK, 
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especially during conditions of rapid air exchange (up to 1.8). Gender differences were 
negligible (Paper III, Tables 7 and 8).  
 
5.3.2 Toluene 
General population 
Considering the general population as a whole, a factor of 1.5 was calculated to cover 
the intraspecies variability of toluene (Figure 11 and Paper IV, Appendix A). The 
CSAFHK derived for children were slightly higher (up to a factor 1.6). Gender 
differences in the toxicokinetics of toluene were small. Thus, 15 year old males had 
slightly higher factors than 15 year old females. The factors for adult females were 
slightly higher compared to the ones for adult males. 
 
Workers 
The variability of surrogate doses representing both chronic and acute effects of toluene 
was covered by a factor 1.6, considering the whole workforce during conditions of 
constant exposure and constant workload (Figures 12 and 13). When fluctuations in 
either exposure or workload were applied, the CSAFHK increased slightly. Combining 
fluctuations in exposure and workload further increased the factors. Slight gender 
differences among workers were observed. Thus, female workers had consistently 
higher CSAFHK than male workers. Under the most extreme assumptions of fluctuating 
workload and fluctuating exposure the factors were 2.0 (chronic) and 3.5 (acute) (Paper 
IV, Appendix B). The rate of air exchange affected the CSAFHK for acute effects. Thus 
the factors were higher during conditions of rapid compared to slow air exchange 
(Figure 13). 
 
5.3.3 Styrene 
General population 
Intraspecies toxicokinetic variability of styrene was represented by a factor of 1.6 in the 
whole population (Figure 11, and Paper IV, Appendix A). According to the 
simulations, the influence factors increased up to 2.1 when including the effect of age. 
Males had slightly higher CSAFHK than females.  
 
Workers 
The CSAFHK for styrene were 1.7 (chronic) and 1.8 (acute), considering the whole 
worker population and conditions of constant exposure level and constant workload 
(Figures 12 and 13). Fluctuations in exposure level or workload increased the factors. 
Further increases were obtained when combining both types of fluctuations. The 
CSAFHK representing chronic effects were higher for male than female workers. 
Conversely, female workers had higher factors for acute effects than males. Hence, the 
highest factors in our simulations were 2.0 (chronic) and 4.7(acute) (Paper IV, 
Appendix B). The rate of air exchange did not markedly affect the factors derived for 
chronic effects. However, rapid air exchange markedly increased the CSAFHK for acute 
effects (Figure 13). 
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Figure 12. CSAFHK for chronic effects in workers during various workplace exposure 
scenarios. The factors for methyl chloride represent workers homozygous for GSTT1 (i.e fast 
conjugators), thus having the highest metabolism in the population. Abbreviations are C; 
constant, E; exposure level, F; fluctuating, R; rapid air exchange and S; slow air exchange, W; 
workload. 
 
 
5.3.4 Methyl chloride 
General population 
A factor of 1.6 covers intraspecies toxicokinetic variability in the general population 
when considered as a whole (Figure 11 and Paper IV, Appendix A). Age had a slight 
influence the CSAFHK. Adult males had slightly higher surrogate doses than adult 
females. The same difference was detected for 15 year old males as compared to 15 
year old females.  
 
Workers 
Among workers, CSAFHK of 1.6 (chronic) and 1.3 (acute) were derived during constant 
exposure and constant workload (Figures 12 and 13). Fluctuations in workload had 
only a slight effect on the derived CSAFHK whereas fluctuations in exposure level 
enhanced variability in surrogate dose. The factors were further increased by a 
combination of fluctuations in exposure level and workload. Male workers had higher 
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CSAFHK for chronic effects whereas females had slightly higher factors based on acute 
markers of effects. Hence, the highest derived CSAFHK in the simulations were 2.0 
(chronic) and 6.1 (acute). The CSAFHK derived for acute effects were increased 
markedly during conditions of raid air exchange (Figure 13). 
 
 
 
Figure 13. CSAFHK for acute effects in workers during various workplace exposure scenarios. 
The factors for methyl chloride represent workers with no conjugation (null genotype), thus 
having the highest blood concentrations of methyl chloride in the population. Abbreviations are 
C; constant, E; exposure level, F; fluctuating, R; rapid air exchange and S; slow air exchange, 
W; workload.  
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 DISCUSSION 6
 
The overall aim of this thesis was to improve the scientific basis for human health risk 
assessment factors. It was achieved by developing a probabilistic framework for the 
derivation of chemical specific assessment factors describing intraspecies differences in 
the toxicokinetics (CSAFHK) of inhaled solvent vapors. The method uses PBPK 
modeling in combination with Monte Carlo simulation from population distributions of 
physiological and biochemical model parameters to simulate surrogate doses in the 
general and worker populations. The effects of age, gender and various workplace 
conditions on the surrogate doses were investigated. CSAFHK were derived for four 
commonly used organic solvents; acetone, toluene, styrene and methyl chloride.  
 
6.1 PROBABILISTIC FRAMEWORK 
As in any modeling exercise, the findings presented in this thesis are influenced by the 
assumptions and considerations made during the development, calibration and 
parameterization of the population PBPK models for acetone, toluene, styrene and 
methyl chloride. They are discussed in detail in the following sections. 
 
6.1.1 PBPK models 
Four different PBPK models were deployed in the derivation of the CSAFHK. The 
acetone PBPK model was developed and calibrated in Papers I and II. PBPK models 
for toluene, styrene and methyl chloride were already described in the scientific 
literature and were hence adopted in the MC simulations in Paper IV. The PBPK 
models have many features in common, but there are also differences. The ones 
considered to be the most influential are discussed below; 
  
Washin-washout effect 
As shown in Paper I, an adequate specification of the inhalatory uptake is important to 
correctly estimate the internal dose of hydrophilic volatiles. The uptake of polar 
solvents such as acetone is largely affected by the influence of washin-washout of 
solvent vapor in the respiratory airways during inhalation and exhalation. The uptake of 
less polar solvents, such as styrene, toluene and methyl chloride, may only be slightly 
or not affected at all. Washin-washout of solvent vapor is described in the PBPK 
models for acetone and styrene. A set of correction factors used to reduce alveolar 
ventilation were sufficient to address the washin-washout of styrene.
103
 The correction 
factors were determined by simultaneous fitting to observed levels of styrene in arterial 
blood and end-exhaled air. In contrast, the washin-washout of acetone (Paper I) was 
described by dividing the lung into 4 separate compartments, and by allowing acetone 
to be exchanged with systemic blood in both the alveolar region and bronchioles. 
Various mathematical descriptions of the washin-washout effect have previously been 
attempted for acetone, but none have succeed in reproducing observed levels of solvent 
in both blood and breath at elevated levels of physical activity.
15,17,127-129
 The acetone 
PBPK model developed in Paper I enabled simultaneous descriptions of acetone levels 
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in arterial blood, and end- and mixed exhaled air, during levels of physical activity up 
to 150W (Section 5.1, Figure 8). 
 
Physical activity 
Exposure to solvent vapors often occurs while performing various tasks requiring 
physical activity, in the workplace as well as in residential settings. Thus, simulations 
of internal doses used to derive CSAFHK were performed by including physical activity 
for the general population as well as for workers. For acetone, workloads of 50W and 
150W for light and heavy exercise respectively were used for all sub-populations 
(Paper III). For toluene, styrene and methyl chloride, the workloads were instead 
determined by matching lung ventilation to reference values for light and heavy 
exercise in each sub-population (Paper IV). The perfusion change during physical 
exercise was accounted for in a similar manner in all four models. To allow for 
differences in blood flow to working and resting muscles, the muscle compartment is 
divided into two.
99
 Similarly, the fat compartment of the toluene and styrene PBPK 
models is divided in two to represent the differences in blood flow to subcutaneous and 
perirenal fat during physical exercise.
95
 The change of the tissue perfusion rates is 
determined by the e cess o ygen u take above rest (ΔV 2) and the workload, except 
for the perfusion change of perirenal fat which was set to the same elevated level 
during all exercise levels.
116,117,95
 According to the model scaling equations adopted 
from Droz and coworkers,
111
 the change of perfusion during physical exercise of well 
perfused tissues, liver and fat is related to BW and BH. However, the increase of the 
blood flow to working muscle is described independent of body size (Paper III, Table 1 
and Paper IV, Table 1).  
 
Perfusion over ventilation ratio  
The perfusion-ventilation ratio (PVR) relates lung ventilation to cardiac output. Thus, it 
is a key parameter in the inhalation PBPK models described in this thesis. In theory, the 
PVR equals 1. However in vivo, it varies between different parts of the lung and 
depends on the position the body is in.
120
 When the PVR differs from 1 inequality or 
mismatch between perfusion and ventilation occurs. Mismatch has been observed 
during physical exercise,
121
 especially during high workloads.
122,123
 Inequality has also 
been suggested in young children as the lung continues to develop until the age of 
approximately 8 years.
124
 However, there is lack of experimental data on the PVR in 
the scientific literature, especially for healthy adult females and children. There is also a 
large variation in the values used in previous models (Paper IV, the Discussion). Due to 
the lack of consistent information, the PVR is one of the most uncertain parameters in 
the simulations.  
 
Metabolism 
In Papers II and III, acetone metabolism was assumed to be first order and described by 
a single clearance parameter. This contrasts the Michaelis-Menten metabolism assumed 
in Paper I, and in the other previous PBPK models for acetone.
125,126
 The reason for 
using a linear model is that the metabolic parameters VMax and Km could not be 
estimated separately in the Bayesian calibration process due to a high correlation 
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between the two (Paper II). The assumption of linear kinetics will have negligible 
impact on the estimates of toxicokinetic variability during exposure to low levels of 
acetone. However, at high exposure levels, such as the ones in an occupational setting, 
metabolism could be partially saturated. Thus, the assumption of linearity had the 
potential to affect the CSAFHK. Additional MC simulations using Michaelis-Menten 
metabolism concluded that the impact of metabolic saturation on the CSAFHK for 
acetone derived for workers was negligible.  
 
The PBPK model for methyl chloride was originally developed for non-conjugators 
and hence did not include metabolism. In Paper IV metabolism was added to the model 
to include also slow and fast metabolizers of methyl chloride. Metabolism was assumed 
to be linear, to occur in blood and was based on human experimental data from adult 
subjects. These choices may influence the CSAFHK for chronic effects, but the effects 
on the CSAFHK for acute effects are expected to be minimal. Those were derived based 
on surrogate doses from non-conjugators, i.e. individuals with no metabolism of methyl 
chloride of methyl chloride. 
 
Predictive power 
The predictive power of a PBPK model may be assessed by applying it to a new data 
set which was not used during model specification. Such a procedure can avoid 
dictation of the choice of model structure or parameterization by the experimental data, 
i.e. over fitting of the PBPK model.
45,127
 Ideally, the available experimental data would 
be divided in two sets - one set which is available during development and refinement 
of the PBPK model and one which is withheld during this phase, and thus may 
represent new data to which the predictions of the finalized PBPK model can be 
compared. In the case of acetone, splitting of the data was performed during the model 
development phase (Paper I). However, to propagate as much information as possible 
to the posterior population distributions of the model parameters, all the experimental 
data were subsequently deployed in the calibration of the acetone PBPK model (Paper 
II). The predictive power of the toluene, styrene and methyl chloride PBPK models was 
not assessed.
95,103,107
  
 
6.1.2 PBPK model calibration 
Calibration of PBPK models to experimental data is essential if the outcome of the 
modeling activities is to be used in health risk assessment of chemical substances.
65
 
Obviously, calibration is dependent on the availability and nature of the experimental 
data. The PBPK models for acetone, toluene, styrene and methyl chloride were 
individually optimized in Bayesian frameworks using MCMC simulation. During a 
Bayesian analysis, prior knowledge on the population distributions of the model 
parameters is increased by adding information contained in experimental toxicokinetic 
data.  
 
Prior knowledge 
Knowledge and experience is individual. Therefore, different persons may draw 
different conclusions from previous knowledge, and thus use different prior 
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distributions. Hence, it has been argued that the Bayesian approach is subjective. The 
idea of a PBPK model is to use biological knowledge in the model specification and 
parameterization. Therefore, published literature values used to derive the prior 
distributions used as starting points for the Markov chains. The reference literature was 
approached in an objective fashion by trying to include all available values while 
giving priority to human in vivo data. In order to comply with the philosophy of 
information gathering in Bayesian statistics, thus incorporating new information based 
on current knowledge, the prior distributions for the physiological model parameters 
were derived from the posteriors resulting from previously calibrated models, when 
available. By this procedure, it is assumed that knowledge on the physiological model 
parameters is fully taken advantage of.  
 
Experimental toxicokinetic data 
The experimental toxicokinetic data for acetone, styrene, toluene and methyl chloride is 
very detailed, i.e. it includes frequent sampling of levels of a chemical substance in 
several biomarkers. However, it comes from a limited number of relatively 
homogenous individuals. The use of such data in PBPK modeling for human health risk 
assessment purposes has both pros and cons. The detailed information offers 
possibilities to gain valuable knowledge on the biological processes that determine the 
toxicokinetics of chemical substances, and hence partially the risk of adversity. 
However, it is not certain that the conclusions are valid for larger and more 
heterogeneous populations. Obviously, experimental studies which include a larger 
number of more diverse volunteers would be helpful in resolving this issue. Such 
studies are however costly and also ethically questionable. However, chemical-specific 
toxicokinetic information from several already conducted experiments can be combined 
by Bayesian population analysis and thus help reduce such uncertainty. The 
experimental data used for calibration of the acetone (Paper II), toluene, styrene and 
methyl chloride (performed in the original studies) PBPK models was derived from a 
total of 56 volunteers, whereof 4 were female. Hence, the experimental data offered 
limited opportunities to access possible age or gender differences in the toxicokinetics 
of the four solvents. The data describe levels of solvent in venous and arterial blood, 
mixed and end-exhaled air during various exposure levels and several different levels 
of physical activity. Thus, it enables the physiological changes occurring during 
physical exercise to be examined. Such information is valuable when it comes to 
quantitative risk assessments based on PBPK modeling of internal dose. Exposure of 
workers, as well as of the general population to organic solvents often occurs in 
conjunction with physical activity.  
 
Sensitivity to prior assumptions 
To investigate the impact of the choice of prior distributions on the outcome, a 
sensitivity analysis was performed within the Bayesian framework during calibration of 
the acetone PBPK model (Paper II). Thus, four different sets of priors were constructed 
where 1, 10, 50 and 100 percent (CV) uncertainty was allowed to surround the prior 
population variability (∑) of the physiological model parameters. As the information in 
the scientific literature regarding population variability was limited, inverse gamma 
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distributions were chosen. They are considered flexible enough to allow the 
experimental data to define variability without making too strict prior assumptions 
about its size.  
 
The results of the sensitivity analysis revealed that the posterior uncertainties increased 
proportionally in relation to the prior. However, the posterior errors remained similar 
regardless of the prior set. This can be explained by a combination of factors. The 
population variability of the physiological model parameters in the acetone PBPK 
model may already to a large extent be accounted for by the scaling to BW and BH 
(Paper II, Table 1). Moreover, as acetone distributes rapidly and evenly in the body, the 
experimental data may have been be too sparse to enable the variability of the model 
parameters to be estimated. It is also possible that the acetone PBPK model is 
insensitive to some of the model parameters. Nevertheless, it seems that allowing for 
extensive flexibility in cases where the information content in the data is low 
(compared to the complexity of the model) seems to create a too large sampling space. 
This behavior has also previously been observed for a complex, mechanistic model.
128
  
 
The results propose that the choice of prior distributions may have a strong influence on 
the posterior distributions. Thus, information on prior sensitivity may be important if 
the results from Bayesian analyses are to be used to estimate health risks. Formal 
sensitivity analyses were not performed during the calibrations of the toluene, styrene 
and methyl chloride PBPK models. However, various sets of priors were tested and 
evaluated throughout the process.
129
 
 
6.1.3 Model parameter distributions 
There is lack of experimental data from females and children, both when it comes to 
experimental toxicokinetic data and PBPK-relevant physiological parameters. In spite 
of representing a large and increasing part of the working population, females are 
generally less often studied than men, and gender differences are not often 
investigated.
130,131
 However, the number of exposure studies which include female 
volunteers has increased in recent years.
132-135
 Obvious ethical reasons limit the 
availability of experimental data from children. Data on physiological parameters for 
children were relatively scarce, especially for the youngest children included in the MC 
simulations. As the Bayesian calibrations were performed with experimental 
toxicokinetic data primarily from adult males the posterior distributions resulting from 
the Bayesian analyses were considered representative of adult males and hence used in 
MC simulations to derive surrogate doses and CSAFHK for adult males. The model 
parameter distributions for adult females and children were instead as far as possible 
collected from the scientific literature. If information was unavailable, the posterior 
distributions were used also for adult females and children. Due to the general lack of 
information, the CSAFHK derived for adult females and children are possibly associated 
with larger uncertainty than the ones obtained for males. 
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Model parameter correlations 
It is well known that physiological parameters correlate. Thus, in this thesis correlations 
were as far as possible accounted for scaling to BW and BH. However, additional 
correlations may exist. In Bayesian calibration, the estimation of one model parameter 
is conditioned not only on the experimental data, but also on the values of all other 
model parameters. Thus, information on additional inter-parameter correlations is 
contained in the converged Markov chains. If parameter values from such chains are 
used as deterministic inputs to the PBPK model, the variability of internal dose may be 
smaller than one would anticipate from the combination of values from separate model 
parameter distributions. The posterior chains were available for acetone, but not for 
toluene, styrene and methyl chloride. For those three, summarized posterior 
distributions were instead used. The parameter distributions for adult female and 
children were in both studies mainly derived from the scientific literature. Thus, only 
the adult male CSAFHK for acetone were derived by including additional parameter 
correlations. The discrepancy may have resulted in a slight overestimation of the adult 
females and children’s CSAFHK for acetone.   
 
6.2 HUMAN TOXICOKINETIC VARIABILITY  
CSAFHK for acetone, toluene, styrene and methyl chloride were derived for various sub-
populations by investigating how factors such as age, gender, endogenous acetone 
levels, workplace ventilation rate and fluctuations in exposure levels and workload 
influenced toxicokinetic variability. The main findings are discussed below. 
 
6.2.1 Age differences 
Age differences were observed for acetone, toluene and styrene (Figure 11). The 
CSAFHK obtained for 5 to 10 years old children were consistently higher than the ones 
for adults and children of other age groups. No age differences were found for methyl 
chloride.  
 
For highly and moderately blood soluble solvents such as acetone (blood; air partition 
coefficient, PBA of 220) and styrene (PBA = 64) the uptake by inhalation is mainly 
governed by the air flow in the lungs, however metabolism and cardiac output are also 
important factors.
26,33,136
 Thus, the larger CSAFHK for acetone and styrene in children 
may in part be e  lained by children’s higher o ygen demand  er kg body weight 
(Paper IV, Table 3) and, as a consequence, higher pulmonary ventilation as compared 
to adults. The higher factors obtained in the 5-10 year old children are probably 
explained by their higher degree of physical activity compared to children of other 
ages, and thus relatively higher exposure by ventilation.
48
 As an equilibrium between 
inhaled air and blood is reached more quickly for less soluble substances such as 
toluene (PBA = 16) and methyl chloride (PBA = 1.7), the effect of ventilation on the 
surrogate doses is less pronounced, or negligible.  
 
The children’s CSAFHK were up to 2.4, thus well below the default factor of 3.16 for 
toxicokinetic differences (Figure 11). However, for acetone, factors higher than the 
default were obtained when including variability from endogenous production (up to 
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5.5 for 3 months old children). This is explained by the higher energy expenditure and 
thus higher endogenous acetone production of children as compared to adults. The 
younger the child the higher the endogenous acetone levels (Paper III, Table 4). 
Healthy levels of acetone in adults are considered to be about 13 mg/l.
137
 However, no 
information regarding healthy levels in children is available. As a comparison, the 
average endogenous level of 3 months old children is 16 mg/l (Paper III, Table 4). 
Thus, there is a possibility that children tolerate a higher body burden of acetone than 
adults.
138,139
 It may also be that they are more sensitive to the effects of ambient 
exposure due to the elevated endogenous production. Extra caution may therefore be 
justified when addressing children’s risk of adverse effects from the exposure to 
acetone. 
 
6.2.2 Gender differences 
Slight gender differences in the toxicokinetics of toluene, styrene and methyl chloride 
were observed (Paper IV, Appendix A and B). Thus, the CSAFHK based on 
metabolized amount (styrene and methyl chloride) were somewhat higher for males 
than for females. For chronic effects of toluene and for acute effects for toluene and 
styrene, female workers had slightly higher factors. No gender differences were 
observed for acetone (Paper III, Tables 6, 7 and 8).  
 
The gender differences may in part be explained by a lower simulated blood flow to the 
fat compartment(s) per kg body weight in females (Paper IV, Tables 2 and 3). Hence, 
females may have higher internal doses of lipophilic solvents and a prolonged exposure 
due to a slower redistribution from fat tissue after exposure has ended.
26
 The gender 
differences found for the two most lipophilic compounds in the MC simulations; 
toluene (partition coefficient between fat and blood, PFatB = 54) and styrene (PFatB = 49), 
are also the most pronounced. Hence, the differences were found to be smaller for 
methyl chloride (PFatB = 6) and in the case of acetone (PFatB = 0.23), not detected. 
However, the differences between genders are small and could therefore also be the 
effect of scaling differences in the four PBPK models. 
 
6.2.3 Workplace conditions 
Fluctuations in exposure level increased the CSAFHK derived for acetone, toluene, 
styrene and methyl chloride. Conditions of rapid air-exchange increased the factors 
more than slow air-exchange, especially those based on acute effect markers. 
Combined effects of fluctuations in exposure level and workload further increased the 
CSAFHK.  
 
The CSAFHK based on chronic markers of effect were all below the default factor of 
1.7-2.2 commonly used for workers (section 3.3.1), also when fluctuations in exposure 
level and workload were combined. In contrast, the factors for toluene, styrene and 
methyl chloride based on acute effects exceeded the default value up to three times 
(Figure 13).  
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The higher factors obtained for acute effects may be explained by a more direct 
relationship of the acute surrogate dose (maximum concentration in blood) with 
fluctuations in ambient exposure level. The factors for acetone were not as markedly 
affected by such fluctuations as the ones for the other three solvents. The difference is 
probably due to the higher blood solubility of acetone compared to toluene, styrene and 
methyl chloride. Indeed, the influence of fluctuations in exposure level was especially 
pronounced for methyl chloride, which has the lowest blood solubility of the four 
solvents. Overall, the results indicate that fluctuations in exposure level and workload 
may be important to consider in the process of setting occupational exposure limits or 
guidelines. 
  
6.2.4 Comparison with previous work 
A limited number of studies have previously used probabilistic PBPK modeling to 
derive assessment factors for intraspecies toxicolinetic variability of inhaled organic 
solvents.
140-148
 The work performed in this thesis is an attempt to include more of the 
available information. Thus, similar to the study by Pelekis and coworkers,
143
 the work 
in Papers III and IV includes the effect of physical activity on the surrogate doses. In 
addition, the simulations herein depart from population distributions of model 
parameters which were calibrated to, and updated by chemical specific toxicokinetic 
data in a statistical framework. 
 
Two previous studies have investigated the effect of age on toluene and styrene 
toxicokinetics, respectively.
141,146
 Nong and Krishnan reported the child to adult 
difference (95
th
/50
th
 percentile) of the internal dose of toluene to be within a factor of 
2.
141
 Similar results were obtained in this thesis, where a factor of 1.6 was derived to 
cover 95 percent of children’s surrogate doses (Paper IV). For styrene, Valcke and 
Krishnan arrived at factors of 1.4 in the adult population, as well as for children 
(95
th
/50
th
 percentiles).
146
 It can be compared to the CSAFHK of 1.2 for adults, and 2.1 
for children obtained in this thesis (Paper IV, Appendix A). The higher factor for 
children obtained herein is most probably due to the higher uptake of solvent vapour 
during  physical activity. 
 
The impact of gender and/or fluctuations in exposure level and workload on the 
toxicokinetic variability among workers has not previously been examined within the 
context of assessment factors.  
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6.3 CONCLUDING REMARKS 
A population PBPK framework for the derivation of data-driven assessment factors for 
intraspecies toxicokinetic differences (CSAFHK) was developed, and applied on four 
organic solvent with different properties (acetone, toluene, styrene and methyl 
chloride). The CSAFHK which were obtained are well suited to replace the default value 
commonly deployed for establishing exposure guidelines or limits. The population 
framework has many advantages. It includes various types of data from already 
conducted experiments and allows for CSAFHK to be calculated not only for the 
population as a whole but also for different subpopulations of interest. The framework 
can be extended to include other chemical substances than the ones presented in this 
thesis, and also to incorporate additional information on human variability when such 
becomes available. Thus, the work presented herein may contribute to establish more 
reliable exposure standards for chemical substances. 
 
The CSAFHK for acetone (excluding endogenous variability), toluene, styrene and 
methyl chloride derived for the general population were at most 2.4, and thus below the 
commonly used default factor of 3.16, also for possibly sensitive sub-populations. 
Fluctuations in exposure level and workload at the workplace have not previously been 
examined within the context of assessment factors. In this thesis they were shown to 
increase the CSAFHK for acetone, toluene, styrene and methyl chloride. The factors 
reflecting acute effects of solvent exposure were up too nearly three times higher than 
the default value typically used for inter-worker variability (1.7-2.2). Thus, fluctuations 
in exposure level and workload may be important factors to consider when 
occupational exposure limits or guidelines are derived. Given the diverse properties of 
these four volatiles, the results can probably be applied on inhalation exposure to 
organic solvents in general. Higher factors may however be obtained for substances for 
which the toxic effect is mediated by an active metabolite, and a majority of the 
population either lacks or has low capacity for this pathway. 
 
To further develop the methodology presented in this thesis, additional data on 
physiological parameters are required, in particular for adult females and children. In 
order to improve the estimates of toxicokinetic population variability of inhaled organic 
solvents, it may be especially important to increase knowledge on the parameters 
determining the physiological changes occurring during physical activity.  
 
During Bayesian calibration of the acetone PBPK model, it was shown that the choice 
of prior distributions had a strong influence on the results. Thus, the use of Bayesian 
methods in toxicological risk assessment may need to be further explored when it 
comes to prior selection, and the impact such may have on the outcome.  
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